ANT008

ANT008 is a second-generation peptide-based antagonist of the vasoactive intestinal peptide (VIP) receptors, specifically VPAC1 and VPAC2. Developed by researchers at Emory University and Cambium Oncology, it is designed to inhibit the immunosuppressive effects of VIP signaling on T cells. By blocking VIP-R signaling, ANT008 enhances T-cell activation and proliferation, potentially improving anti-tumor immune responses in hematologic malignancies such as acute myeloid leukemia (AML) and T-cell lymphoblastic leukemia. In preclinical studies, it has demonstrated the ability to increase the expression of activation markers like CD69 and OX40 on human CD4+ and CD8+ T cells, although it is reported to be less potent than other candidates in the same series, such as ANT308 and ANT195.